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A B S T R A C T
Nitro-oleate (10-nitro-octadec-9-enoic acid), which inhibits soluble epoxide hydrolase (sEH) by covalently adducting to C521, increases the abundance of epox-
yeicosatrienoic acids (EETs) that can be health promoting, for example by lowering blood pressure or their anti-inflammatory actions. However, perhaps consistent
with their impact on angiogenesis, increases in EETs may exacerbate progression of some cancers. To assess this, Lewis lung carcinoma (LLc1) cells were exposed to
oleate or nitro-oleate, with the latter inhibiting the hydrolase and increasing their proliferation and migration in vitro. The enhanced proliferation induced by nitro-
oleate was EET-dependent, being attenuated by the ETT-receptor antagonist 14,15-EE-5(Z)-E. LLc1 cells were engineered to stably overexpress wild-type or C521S
sEH, with the latter exhibiting resistance to nitro-oleate-dependent hydrolase inhibition and the associated stimulation of tumor growth in vitro or in vivo. Nitro-
oleate also increased migration in endothelial cells isolated from wild-type (WT) mice, but not those from C521S sEH knock-in (KI) transgenic mice genetically
modified to render the hydrolase electrophile-resistant. These observations were consistent with nitro-oleate promoting cancer progression, and so the impact of this
electrophile was examined in vivo again, but this time comparing growth of LLc1 cells expressing constitutive levels of wild-type hydrolase when implanted into WT
or KI mice. Nitro-oleate inhibited tumor sEH (P < 0.05), with a trend for elevated plasma 11(12)-EET/DHET and 8(9)EET/DHET (dihydroxyeicosatrienoic acid)
ratios when administered to WT, but not KI, mice. Although in vitro studies with LLc1 cells supported a role for nitro-oleate in cancer cell proliferation, it failed to
significantly stimulate tumor growth in WT mice implanted with the same LLc1 cells in vivo, perhaps due to its well-established anti-inflammatory actions. Indeed,
pro-inflammatory cytokines were significantly down-regulated in nitro-oleate treated WT mice, potentially countering any impact of the concomitant inhibition of
sEH.
1. Introduction
Epoxyeicosatrienoic acids (EETs) are a cytoprotective, health-pro-
moting class of lipids that limit the progression of several diseases [1].
Consistent with this, there have been significant efforts to develop in-
hibitors of soluble Epoxide Hydrolase (sEH) [1,2], which otherwise
degrade EETs to their corresponding dihydroxyeicosatrienoic acids
(DHETs) that may lack the protective bioactivity profile of the disease-
combatting epoxy lipids. sEH inhibitors offer broad cardiovascular
protection, including blockade of smooth muscle cell proliferation and
development of atherosclerosis [1,3,4]. Additionally, they are anti-hy-
pertensive and limit the progression of myocardial hypertrophy, heart
failure and fibrosis. They also attenuate injury during ischemia in the
heart, brain and other organs [5–7].
Nitro-fatty acids, including nitro-oleate, are found endogenously in
animals, including humans [8–10]. The classical ‘Mediterranean diet’
also supplies nitro-oleate, as well as nitrite- and nitrate-rich vegetables
together with unsaturated fats from fish or plants [11]. The nitrite
combines with the unsaturated oils in the acidic stomach environment
to generate nitro-fatty acids [12]. We previously showed nitro-oleate
(10-nitro-octadec-9-enoic acid, NO2-OA), as well as other lipid elec-
trophiles such as 15-deoxy-prostaglandin J2, adduct to C521 near the
catalytic centre of sEH to cause inhibition [13]. The importance of C521
in this inhibition was corroborated by subsequent studies with C521S
sEH knock-in (KI) mice engineered to be resistant to hydrolase inhibi-
tion by lipid electrophiles [14]. Nitro-oleate increased the EET/DHET
ratio, lowered blood pressure and attenuated myocardial hypertrophy
in angiotensin II-induced hypertensive wild-type (WT), but not KI,
mice. Thus, it was concluded that inhibition of sEH by nitro-oleate
explained at least some of the cardiovascular protection by the Medi-
terranean diet [14], which is rational considering the health-promoting
actions of conventional inhibitors of the hydrolase, as outlined above.
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sEH inhibitors also show therapeutic promise in the treatment of
tissue ischemia, perhaps in part because EETs promote angiogenesis
and so tissue revascularisation [15]. On the other hand, elevated levels
of EETs can also enhance tumor vascularisation and growth in vivo
[16–19]. Indeed, patients with a history of malignancy are excluded
from clinical trials with sEH inhibitors, including recently tested com-
pounds [15]. Elevated dietary nitrite, which may potentially combine
with endogenous unsaturated fatty acids to yield nitro-lipid inhibitors
of sEH, has been implicated epidemiologically as a risk factor for cancer
[20], although there are substantive confounding factors that limit
causality being established [21]. Furthermore, there is conflicting evi-
dence that nitro-lipids exert anti-cancer effects, attenuating prolifera-
tion and migration of triple negative breast cancer cells [22]. With
these considerations in mind, we performed studies to assess whether
nitro-oleate can enhance tumor proliferation and growth. The mouse
Lewis lung carcinoma cell line (LLc1) cells were selected for study as
there was evidence that exogenously applied EETs enhance their
growth in vivo when they are implanted in mice [17]. LLc1 cells stably
overexpressing sEH, but not C521S sEH, showed potentiated growth in
response to nitro-oleate in vitro or when engrafted into C57BL/6 mice.
In contrast, whilst LLc1 cells expressing constitutive amounts of sEH
showed potentiated proliferation in response to nitro-oleate, such a
growth enhancement was not observed when these cells were engrafted
to WT or KI mice. This may be because the anti-inflammatory actions of
nitro-lipids, which may in part be due to their ability to increase ETT
levels, may offset their potential for promoting aberrant cancer growth.
2. Material and methods
2.1. Transgenic mice generation and study approval
The KI transgenic mouse line was generated by site-directed
Fig. 1. Nitro-oleate increased proliferation and migration of LLc1 cells through inhibition of sEH and EET signalling
(A) 5 μM or 10 μM nitro-oleate reduced sEH activity. In contrast, sEH activity was not reduced by the non-electrophile oleate (N=12 per group from 3 independent
experiments). The time graph shows that sEH-dependent hydrolysis of PHOME to 6-methoxy-2-naphtaldehyde (6M2N), which is fluorescent, is linear over 60 min.
(B-D) Real-time monitoring of LLc1 cell proliferation (cell index) and proliferation rates calculated from these measurements. (B) 5 μM or 10 μM nitro-oleate
stimulated proliferation compared to untreated or DMSO-treated control cells (N=4 independent experiments). (C) In addition, oleate did not stimulate cell pro-
liferation (N=4 independent experiments). (D) The increased proliferation induced by 5 μM nitro-oleate was normalized by the EET antagonist 14,15-EE-5(Z)-E
(N=4 independent experiments). (E) Real-time monitoring of LLc1 cells trans-well migration (cell index) and migration rates calculated from these measurements.
5 μM nitro-oleate stimulated transmigration compared to untreated or vehicle (DMSO)-treated control cells (N=4 independent experiments). *P < 0.05 sig-
nificantly different compared to untreated control. #P < 0.05 significantly different compared to the nitro-oleate treated group.
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mutagenesis as previously described [13,14]. All procedures were
performed in accordance with the Home Office Guidance on the Op-
eration of the Animals (Scientific Procedures) Act 1986 in the United
Kingdom and were approved by a King's College London Animal Wel-
fare and Ethical Review Body.
2.2. Cell culture and cell isolation
The LLc1 cell line (ECACC 90020104) was purchased from the
European collection of authenticated cell cultures, and cultured in
DMEM containing 2 mM L-glutamine, 10% fetal bovine serum and an-
tibiotics (Invitrogen). Mouse aortic endothelial cells (ECs) were isolated
from KI or their WT littermates as previously described [23]. Briefly,
harvested arteries were digested with 0.05% collagenase type 2 (Gibco)
to yield cells that were stained with a CD31 antibody (E-bioscience) and
then sorted using a Fluorescence-activated cell sorting Aria II (BD
Biosciences). CD31 positive ECs were cultured in the EC growth
medium EGM-2MV (Lonza).
2.3. Cell transfection and stable cell line
LLc1 cells were plated in 6-well plates at 50% confluence. The fol-
lowing day cells were transfected with 20 μg of plasmid encoding WT
sEH or C521S sEH encoded in a pcDNA 3.1 TOPO Vector (Thermo
Fisher Scientific) pre-mixed with Lipofectamine 2000 (Thermo Fisher
scientific). To select clones that stably expressed V5-tagged WT or
C521S sEH, cells were exposed to geneticin (Thermo Fisher Scientific),
which was replaced daily for 10 days. The stability of protein expres-
sion was evaluated by immunoblotting using an antibody to sEH
(Cayman) and the V5 tag (Abcam), with selected clones expanded for
use in subsequent experiments.
2.4. Proliferation and migration assay
For cell proliferation and migration assays, an xCELLigence Real-
Time Cell Analyzer DP instrument (ACEA Biosciences) was used. For
LLc1 cell proliferation assays, 3000 cells were seeded per well for the
experiments shown in Fig. 1B and D, whereas 1000 cells were seeded
for that shown in Figs. 1C and 2C. Nitro-oleate, oleic acid (oleate), 12-
(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), the selective EET
antagonist 14,15-Epoxyeicosa-5(Z)-enoic Acid (14,15-EE-5(Z)-E) or di-
methyl sulfoxide (DMSO) was mixed with 5% FBS in DMEM. Growth
rate was measured automatically every hour. For migration assays,
2 × 104 serum-starved LLc1 cell or ECs were mixed with 5 μM nitro-
oleate or DMSO and seeded on the upper chamber of a 16-well CIM-
plate (ACEA Biosciences). DMEM or EBM-2 with 2% FBS were loaded in
the lower chamber of the CIM-plate and migration rate was measured
every 30 min.
2.5. sEH activity assay
Cells treated with nitro-oleate, AUDA or DMSO were harvested and
lysed in 0.5% digitonin lysis buffer and centrifuged at 3000 g for
5 min at 4 °C. Whole tumor tissues were homogenized on ice in 100 mM
Tris-buffered saline (pH7.4) supplemented with a protease inhibitor
cocktail (Roche) using a tissue homogenizer (CAT Scientific) (10%
volume/volume). sEH activity was measured using a 3-phenyl-cyano(6-
methoxy-2-naphthalenyl)methyl ester-2-oxiraneacetic acid (PHOME,
Cayman) as a substrate, which becomes highly fluorescent when its
epoxide group is hydrolysed to 6-methoxy-2-naphtaldehyde (6M2N).
Cell lysates or tissue homogenates were mixed with or without AUDA to
a final concentration 50 μM for 5 min at 37 °C to allow the contribution
of sEH to total PHOME hydrolysis to be defined. Subsequently PHOME
to a final concentration 20 μM was mixed and fluorescence measure-
ments made at excitation 330/emission 465 nm every 2 min for 1 h
using a CLARIOstar plate reader (BMG Labtech) at 37 °C. In some
studies an endpoint assay was performed, making the measurement as
above after 1 h. Protein concentration were measured using the bi-
cinchoninic acid assay [13,14,24].
2.6. Aorta ring assay
Thoracic aorta isolated from WT or KI mice were cut into ~2 mm
pieces and embed in 96 well plates coated with Matrigel (Corning).
Aortas were incubated with 5 μM nitro-oleate or 50 ng/ml vascular
endothelial growth factor (VEGF). After 14 days, sprouted vessel length
was measured using image J software as before [23].
2.7. Mouse tumor implantation model
1 × 106 LLc1 cells were subsequently injected in WT or KI male
mice (12–14 weeks of age). For the study utilising genetically-modified
LLc1 cells stably overexpressing WT or C521S sEH, 1 × 105 cells were
injected in C57BL/6 mice. After the tumor size reached ~100 mm3, the
mice were treated with vehicle (50% saline with 50% DMSO) or 5 mg/
kg/day nitro-oleate or oleate using osmotic pumps (ALZET). Tumor
volume, which was not allowed to exceed 1.5 cm3, was measured every
2 or 3 days using a calliper. sEH activity and protein expression
(Cayman) were measured in harvested tumor tissues. In addition, par-
affin-embedded sectioned tumor tissues were stained using Alexa
Fluor™ 568 Conjugate isolectin B4 (Thermo Fisher scientific) and DAPI
(Sigma). Stained sections were visualized using a Nikon eclipse TS100
fluorescence microscope and isolectin B4 positive cells were counted
using Image J software [23]. Plasma was analysed for the EETs and
DHETs as described below, and cytokines (interleukin (IL)-1β, IL-6, IL-
10 and IL-12p70) analysed using a Bio-Plex multiplex immunoassay kit
(Bio-Rad) with a Bio-Plex MAGPIX fluorescence magnetic bead-based
immunoassay reader (Bio-Rad) according to the manufacturer's in-
structions.
2.8. EET and DHET measurement
Plasma samples were prepared in an antioxidant solution com-
prising 0.2% triphenylphosphine, 0.2% butylated hydroxytoluene and
1% ethylenediaminetetraacetic acid. To isolate lipids, plasma samples
(100 μl) were first spiked with 20 ng each of 5(6)-EET-d11, 8(9)-EET-
d11, 11(12)-EET-d11,-14(15)-EET-d11, 8(9)-DHET-d11, 11(12)-DHET-
d11 and 14(15)DHET-d11 (Cayman), as internals standards and
brought to 500 μl with PBS. Next, 2 ml of chloroform: methanol (2:1)
was added and the samples were vortexed and centrifuged at
2500 rpm at 10 °C for 10 min. Next the organic phase was transferred to
a new tube and dried under nitrogen, after which samples were subject
to saponification with 1 ml of 1 M NaOH for 90 min at room tem-
perature. After acidification (pH ~4), lipids were extracted with 4 ml of
ethyl acetate, dried under nitrogen and reconstituted in 100 μl of me-
thanol for analysis. Samples were injected (10 μl) into a Shimadzu
HPLC with CTC PAL autosampler coupled to a Sciex 5000 triple
quadrupole (Sciex). EETs and DHETs were separated on a Phenomenex
Luna C18 reversed phase column (2.1 × 100 mm, 5 μm) with Solvent
(A) water + 0.1% acetic acid and (B) acetonitrile + 0.1% acetic acid at
0.6 ml/min under the following gradient conditions: 0 min 30%B
ramping up to 90%B at 10 min and holding until 15 min followed by a
2 min wash at 100%B and a 3 min equilibration at starting conditions.
EETs and DHETs were monitored with the following MRM transitions in
negative ion mode: m/z 319.5.191.1 5(6)EET, m/z 330.5.202.1, 5(6)
EET-d11, m/z 337.5.145.1 5(6)DHET, m/z 319.5.155.1 8(9)EET, m/z
330.5.167.1 8(9)EET-d11, m/z 337.5.127.1 8(9)DHET, m/z
348.6.127.1 8(9)DHET-d11, m/z 319.5.167.1 11(12)EET, m/z
330.5.167.15 11(12)EET-d11, m/z 337.5.167.1 11(12)DHET, m/z
348.6.167.1 11(12)DHET-d11, m/z 319.5.219.1 14(15)EET, m/z
330.5.219.1 14(15)EET-d11, m/z 337.5.207.1 14(15)DHET, m/z
348.6.207.1 14(15)DHET-d11. EETs and DHETs were quantified using
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Fig. 2. Nitro-oleate-induced tumor growth is dependent on C521 in vitro and in vivo
(A) LLc1 cells engineered to stably overexpress WT or C521S sEH do so, as detected by immunoblotting with an antibody to the hydrolase or the V5 tag that the
recombinant proteins also carry. The immunoblots are representative of 3 independent experiments. (B-C) 5 μM nitro-oleate decreased sEH activity and stimulated
proliferation compared to untreated or oleate-treated LLc1 cells overexpressing WT, but not C521S, sEH (N=4 independent experiments). *P < 0.05 significantly
different compared to untreated WT sEH LLc1 cells. (D-E) 5 mg/kg/day nitro-oleate, oleate or vehicle was administered to mice after their implantation with LLc1
cells overexpressing WT or C521S sEH. Nitro-oleate, but not oleate nor vehicle, stimulated growth in mice with LLc1 cells overexpressing WT, but not C521S, sEH.
Nitro-oleate, but not oleate, selectively reduced activity in cells overexpressing the WT hydrolase (N=6–8 per experimental group from 3 independent experiments).
(F) IL-1β, IL-6, IL-10, IL-12p35 and IL-12p40 abundance in tumor tissue was decreased in LLc1 cells overexpressing WT sEH upon exposure to nitro-oleate. These
cytokines were lower in abundance basally in tumor tissue derived from cells expressing C521S sEH compared to those overexpressing WT hydrolase. In contrast to
tumors originating from cells expressing WT hydrolase, those derived from cells expressing C521S sEH did not change their cytokine abundance when exposed to
nitro-oleate (N=6–8 per experimental group from 3 independent experiments). *P < 0.05 significantly different compared to LLc1 cells expressing WT sEH exposed
to vehicle.
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standard curves of analyte to internal standard. Because no ISTD is
available for 5(6)-DHET, the 8(9)-DHET-d11 ISTD was used. EETs and
DHETs are reported as a ratio.
2.9. Real-time PCR
Total RNA was extracted from harvested tumor tissues using an
RNAesay-Mini Kit (Qiagen), and synthesised complementary DNA
(Thermofisher) following the manufacture's protocol. All samples were
performed triplicate, and 2 ng cDNA was used with a SYBR-Green
(Invitrogen). To measured cytokine expression, IL-1β, IL-6, IL-10, IL-
12p35, and IL-12p40 primer were used. cDNA expression were nor-
malized by GAPDH primer was used for the thermal cycler conditions
were performed as follows manufacture's manual (Quant Studio 5,
Thermofisher). Designed primers were as follows: IL-1β Forward:
GAAATGCCACCTTTTGACAGTG, Reverse: TGGATGCTCTCATCAGGA
CAG, IL-6 Forward: GGAGCCCACCAAGAACGATAG, Reverse: GTGAA
GTAGGGAAGGCCGTG, IL-10 Forward: GCTGGACAACATACTGCTA
ACC, Reverse: ATTTCCGATAAGGCTTGGCAA, IL-12p35 Forward: GGT
GAAGACGGCCAGAGAAA, Reverse: GTAGCCAGGCAACTCTCGTT, IL-
12p40 Forward: TTCCCTGTCGCTAACTCCCT, Reverse: GTGGAGACAC
CAGCAAAACG and GAPDH Forward: AGGTCGGTGTGAACGGATTTG,
Reverse: GGGGTCGTTGATGGCAACA (PrimerBank). The relative
mRNA expression levels were normalized with GAPDH and calculated
using the ‘delta-delta Ct’ method.
2.10. Statistical analysis
Difference between groups was calculated by a Student t-test or
analysis of variance followed by a Tukey post-hoc test. P < 0.05 was
considered significantly different.
3. Results
3.1. Nitro-oleate inhibits sEH and increases cancer cell proliferation and
migration
5 or 10 μM nitro-oleate, but not the vehicle DMSO, inhibited sEH to
a comparable extent to that induced by the established pharmacological
hydrolase inhibitor AUDA. In contrast, oleate, which is not electro-
philic, did not inhibit sEH (Fig. 1A). Treatment of LLc1 cells with nitro-
oleate significantly increased their proliferation rate compared to ex-
posure to vehicle alone or treatment with oleate (Fig. 1B-C). The EET
receptor antagonist 14,15-EE-5(Z)-E attenuated the nitro-oleate-in-
duced proliferation of LLc1 cells (Fig. 1D), consistent with the enhanced
growth being mediated by increased abundance of EETS that arises due
Fig. 3. Nitro-oleate increased migration of ECs from WT but not C521S sEH KI mice.
(A) Real-time monitoring of ECs trans-well migration (cell index) and migration rates calculated from these measurements. 5 μM nitro-oleate stimulated trans-
migration in ECs from WT, but not KI, mice compared to untreated controls (N=4 independent experiments). (B) Representative images from an ex vivo vessel
sprouting assay and vessel sprout length calculated from these data. Nitro-oleate increased vessel sprout length as much as VEGF in WT but failed to do so in
preparations from the KI mice (N=4 independent experiments). Scale bars show 200 μm *P < 0.001 significantly different compared to untreated WT control,
#P < 0.001 significantly different compared to untreated C521 sEH KI control. #P < 0.05 significantly different compared to the nitro-oleate treated WT group.
H.-J. Cho, et al. Redox Biology 29 (2020) 101405
5
to electrophilic inhibition of the hydrolase. In addition, 5 μM nitro-
oleate dramatically increased migration of LLc1 cells compared to those
exposed to vehicle alone (Fig. 1E).
3.2. Nitro-oleate-induced tumor growth is dependent on sEH Cysteine 521
To investigate whether nitro-oleate induced tumor growth by its
electrophilic adduction to C521 of sEH, we generated LLc1 cells stably
overexpressing WT sEH or C521S sEH. Immunoblotting analysis and
sEH activity analysis of whole cell lysates confirmed robust over-
expression of active hydrolase in each of the stable cells lines generated
(Fig. 2A). Nitro-oleate increased proliferation and decreased sEH ac-
tivity in LLc1 cells stably overexpressing WT sEH, but not those with the
C521S mutant (Fig. 2B-C). LLc1 cells stably overexpressing WT or
C521S sEH were implanted into WT C57BL/6 mice and then exposed to
nitro-oleate or oleate. LLc1 cells expressing WT sEH exhibited po-
tentiated tumor growth and decreased sEH activity in response to nitro-
oleate, but not oleate. However, the LLc1 cells stably overexpressing
C521S sEH showed significantly slowed tumor growth compared to sEH
LLc1 cell injected group that was not accelerated by nitro-oleate
treatment (Fig. 2D-E).
3.3. Nitro-oleate-stimulated EC migration is dependent on sEH Cysteine 521
The increase in migration of LLc1 cell induced by nitro-oleate, a
treatment that was also associated with inhibition of sEH, is likely
mediated by adduction of the electrophile to C521 of the hydrolase. To
test the importance of C521 in the stimulation of cell migration, ECs
were isolated from WT or KI mice and exposed to nitro-oleate. Nitro-
oleate significantly increased WT EC migration but failed to in cells
isolated from the KI mice (Fig. 3A). The impact of nitro-oleate was next
assessed using an ex vivo aortic ring sprouting assay, comparing the
responses of aortic rings isolated from WT to those from KI mice. VEGF,
which stimulates angiogenesis in this model and so served as a positive
control, increased vessel sprouting to the same extent in vessels isolated
from mice of either genotype. In contrast, although nitro-oleate sig-
nificantly increased sprouting of vessels from WT, this did not occur in
those isolated from KI mice (Fig. 3B).
3.4. The impact of nitro-oleate on tumor growth in vivo
It was evident that nitro-oleate stimulated growth and migration of
LLc1 cells or ECs, and mechanistically this was at least in part mediated
by inhibition of sEH via adduction to C521. However, these conclusions
are based on studies with LLc1 cells that overexpressed the hydrolase
above levels found constitutively. Consequently, LLc1 cells expressing
normal, constitutive amounts of sEH were implanted into WT or KI mice
and their growth responses to vehicle or nitro-oleate were determined
by serially measuring tumor volume over time. Tumor volume in-
creased over time in all experimental groups (Fig. 4A-C), with a trend
towards nitro-oleate enhancing the rate of growth in WT (P=0.07),
whereas it had no such effect in the KI. However, the overall increase in
growth was relatively subtle (Fig. 4A), and despite having 12–15 mice
per group failed to reach the 5% significance level.
3.5. Nitro-oleate inhibits sEH activity in WT mice and increases EETs
The impact of nitro-oleate on tumor sEH activity and plasma EETs
levels was determined 16-days after implantation of LLc1 cells, com-
paring the response of each genotype to treatment with or without
nitro-lipid. Tumor sEH expression was not different between genotypes
or altered by exposure to nitro-oleate (Fig. 4D). However, tumor sEH
activity in the nitro-oleate treated group was decreased compared to the
vehicle treated group in WT mice (P < 0.05), although this was not
observed in the xenografts implanted in the KI mice when they were
exposed to the electrophile (Fig. 4E). However, although nitro-oleate
reduced sEH activity to a statistically significant extent in tumors im-
planted in the WT mice, the magnitude of the reduction was rather
subtle. In an attempt to gain additional insight to the relationship be-
tween tumor growth and sEH activity in mice of either genotype ex-
posed or not to nitro-oleate, correlation analyses were performed
(Fig. 4F). Only one experimental group, namely WT mice implanted
with a tumor and exposed to nitro-oleate, showed a significant corre-
lation (P < 0.05). The relationship observed showed that in tumor-
bearing WT mice treated with nitro-oleate, smaller tumors correlated
with higher sEH activity. However, we acknowledge that despite a
statistically significant correlation being observed, that the low sample
size in these studies limits confidence in these data and so definitive
conclusions cannot be drawn. The ratio of 14(15)-, 11(12)-, 8(9)- and
5(6)-EET/DHET was measured in plasma in WT or KI mice harboring
tumors exposed to vehicle or nitro-oleate. Although, this analysis did
not identify any statistical differences between experimental interven-
tions, it was notable that the WT mice exposed to nitro-oleate showed a
trend for increased ratios of plasma 14(15)-, 11(12)- and 8(9)-EET/
DHET. However, it should be noted that the KI mice also showed a
similar trend towards increased EET/DHET ratios for all measurement
performed, with the 14(15)-EET/DHET ratio reaching statistical sig-
nificance (Fig. 4G). Staining of vascular ECs using isolectin B4 or CD31
as a vascularisation marker showed increased blood vessel density in
the nitro-oleate treated group of WT mice, whereas in KI mice this in-
tervention had no impact compared to vehicle control (Fig. 4H).
3.6. Nitro-oleate modulates inflammatory cytokine production
Nitro-oleate is well-established as having anti-inflammatory actions
[12,25–28], whereas inflammation is associated with alteration in cy-
tokine profile that may contribute to cancer development [29]. Con-
sequently, plasma and tumor tissue levels of pro-inflammatory cyto-
kines were measured in mice of either genotype implanted with tumors
exposed to vehicle or nitro-oleate. Nitro-oleate decreased IL-1β and IL-
12 levels in tumor-bearing WT mice compared to vehicle. However, the
KI mice that carried tumors had markedly lower levels of several cy-
tokines, namely IL-1β, IL-6, IL-12p70 and IL-10, regardless of whether
they had been exposed to vehicle of nitro-oleate (Fig. 4I). These data
are consistent with nitro-oleate altering the inflammatory cytokine
profile, which may modulate tumor growth, as discussed below.
4. Discussion
The electrophile nitro-oleate inhibited sEH in LLc1 cells, which
stimulated proliferation and migration of these lung cancer cells in vitro.
This mirrors previous studies that showed nitro-oleate, along with some
other lipid electrophiles, inhibited hydrolysis of EETs by covalently
adducting to Cysteine 521 [14], which is located within the hydro-
phobic tunnel substrate domain proximal to the hydrolase active site
[13]. As the reputed EET-receptor antagonist 14,15-EE-5(Z)-E also at-
tenuated the proliferation stimulated by nitro-oleate, this supported a
causal role for EET-induced signalling in the growth response induced
by the electrophile. The modification of C521 by nitro-oleate likely
causatively mediated the inhibition and enhanced proliferation and
migration in vitro, as LLc1 cells engineered to stably overexpress C521S
sEH that cannot be modified by the electrophile were resistant to these
events. In contrast, LLc1 cells stably overexpressing WT sEH responded
like normal LLc1 cells with constitutive amounts of the hydrolase to
nitro-oleate in vitro, namely attenuation of EET hydrolytic activity to-
gether with enhanced proliferation and migration. The stable cell lines
overexpressing sEH were also studied in vivo, by implanting them into
C57BL/6 mice and monitoring tumor growth over time. These in vivo
studies gave comparable results to those with these cells in vitro, such
that cells overexpressing WT, but not C521S, sEH exhibited potentiated
growth in response to nitro-oleate. This promotion of tumor growth in
vitro as well as in vivo by nitro-oleate-dependent inhibition of sEH is
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consistent with observations made using other well-established hydro-
lase inhibitors. For example, trans-4-[4-(3-adamantan-1-yl-ureido)-cy-
clohexyloxy]-benzoic acid (t-AUCB), which reversibly binds the a pair
of aspartic acid residues in the active site, is a potent sEH inhibitor that
enhanced proliferation and migration of LLc1 cells in vitro as well as
tumor growth when explanted to mice [17,30]. It was notable that the
LLc1 cells expressing WT sEH grew faster when implanted into mice
compared to the C521S variant, even in the absence of nitro-oleate,
which perhaps reflects differential adduction and inhibition of the hy-
drolase by endogenous electrophiles.
A limitation of these experiments discussed above was the over-
expression of the hydrolase, and so we next compared the growth of
LLc1 cells expressing normal levels of sEH, implanting these cells into
transgenic C521S sEH mice or their WT controls and comparing tumor
growth in response to vehicle or nitro-oleate. Whilst there was a minor
trend for nitro-oleate to increase the rate of tumor growth, this was not
statistically significant. This failure was despite experimental group
sizes of 12–15, providing confidence in the observation. We should
consider that the genotype of the murine host is different, but that the
tumor cells themselves are identical. Thus, the potential differential
responses between genotypes, in which the tumors implanted in KI
mice were not stimulated to grow by nitro-oleate, likely reflect dis-
parate responses of the host tissues and not the tumor cells themselves.
Once host ECs or immune cells invade the tumor, this would potentially
provide a plausible mechanistic explanation for the differential tumor
vascularisation and growth responses to nitro-oleate depending on the
genotype to which the LLc1 cells were implanted. Indeed, aorta isolated
from WT mice showed angiogenic vessel sprouting in response to nitro-
oleate, whereas vessels from the KI mice did not. In contrast, vessels
from either genotype responded identically to the angiogenesis-stimu-
lator VEGF, consistent with the differential responses to electrophiles in
the KI being mediated by modification of C521.
Although nitro-oleate inhibited WT, but not C521S, tumor sEH ac-
tivity, as may be expected based on the findings so far, there was sig-
nificant additional complexity. For example, although there was a trend
for the nitro-oleate to increase the plasma EET/DHET ratio for the re-
gioisomer pairs measured, this did not reach statistical significance.
Furthermore, KI mice also showed a similar trend with the 14(15)-EET/
DHET ratio reaching statistical significance, which is notably different
than the other observations reported here, in which the C521S mutation
renders the hydrolase unresponsive to nitro-oleate. As the tumor cells
only express WT sEH, at normal levels, perhaps this explains this ob-
servation at least in part, as even when they are implanted to KI mice,
their hydrolase can still be inhibited by the nitro-lipid to potentially
increase EET abundance. Ideally, we would also have measured other
metabolic products of EETs, as well as plasma EETs and DHETs in mice
that were not implanted with tumors, but this was not possible for us.
We should also consider that EETs abundance are modulated by several
pathways in addition to sEH that generates DHETs. These include me-
tabolism by β- or ω-oxidation, as well as by phospholipase or cy-
clooxygenase [31–34]. EETs can also esterified, with the free, un-
esterified forms accounting for ~3% of rat plasma EETs [35]. This
esterification may decrease the abundance and signalling processes
associated with free EETs [31]. Although esterified EETs can have
regulatory functions themselves, such as ion transport control [36,37],
a complete understanding remains to be elucidated [38]. In addition,
the relationship between esterified EETs and cancer progression is also
incompletely understood. Herein we have specifically focused on con-
version of EETs to DHETs and hydrolase activity. In this connection,
whilst a sEH inhibitor increased tumor size [17], co-administration of
the cyclooxygenase-2 inhibitor celecoxib dramatically attenuated this
growth response [30,34,39]. Consistent with this, 4-(5-phenyl-3-(3-[3-
(4-trifluoromethyl-phenyl)-ureido]-propyl)-pyrazol-1-yl)-benzenesulfo-
namide (PTUPB), which inhibits both sEH and cyclooxygenase, sy-
nergistically suppressed tumor growth [34,40] and potentiated the anti-
cancer effect of cisplatin [41]. It seems clear that sEH inhibition com-
bined with anti-inflammatory interventions can afford synergistic anti-
cancer activities. As nitro-lipids inhibit sEH as well as anti-in-
flammatory actions, this may explain the lack of a statistically sig-
nificant increase in LLc1 tumor growth in vivo. The anti-inflammatory
actions are mediated at least in part by attenuating formation of cy-
clooxygenase-derived proangiogenic metabolites of EETs [34]. Inhibi-
tion of sEH alone would generate more substrates for formation of these
proangiogenic metabolites, but inhibition of cyclooxygenase-2 would
attenuate their formation and limit cancer growth.
Correlation analysis of the relationship between sEH activity and
tumor size at the end of the protocol was performed for each of the four
experimental groups, namely mice of either genotype administered
vehicle or nitro-oleate. Notably, this showed that there was a statisti-
cally significant relationship only in one of these four groups, namely
the WT mice exposed to nitro-oleate – with bigger tumors being asso-
ciated with lower hydrolase activity. These analyses showed again that
nitro-oleate inhibited sEH and this was associated, perhaps causatively
considering the data presented here in its entirety, with enhanced
tumor growth. Panigraphy et al. showed sEH expression was reduced to
a greater extent in larger tumors over 5 cm3, with no alteration in ex-
pression in those smaller than 1 cm3 [17]. In our study, sEH expression
changes were not detected. However, because of mouse welfare con-
siderations tumors were not allowed to develop beyond 1.5 cm3 and so
cannot be directly compared to this previous study.
Besides inhibiting sEH activity, nitro-oleate can also exert anti-in-
flammatory actions, with several studies study showing it lowered the
abundance of the cytokines IL-1β, IL-6 and IL-12 induced by exposure
to lipopolysaccharide or IL-4, although other anti-inflammatory cyto-
kines such TGFβ and IL-10 were also downregulated [25,27,28]. In
addition, sEH inhibition also has a strong anti-inflammatory action
Fig. 4. Impact of nitro-oleate on LLc1 tumor growth
(A-C) Temporal measurement of tumor volume in WT or C521S sEH KI mice during treatment with vehicle or 5 mg/kg/day nitro-oleate after implantation with LLc1
cells. The area under the curve for tumor volume was calculated from these data. Nitro-oleate stimulated tumor growth compared to vehicle in WT mice, although
this failed to reach statistical significance at the 5% level (P=0.07). In contrast, there was no difference in tumor volume with or without nitro-oleate treatment in KI
mice (N=12–15 mice were studied per experimental group). (D) Tumor sEH expression was not different between genotypes or altered by nitro-oleate treatment. (E)
sEH activity in tumor tissue harvested from WT mice was lower in those from mice exposed to nitro-oleate compared to those only administered vehicle. In contrast,
the nitro-lipid did not modulate hydrolase activity present in tumors isolated from KI mice (N=12–15 mice were studied per experimental group). (F) sEH activity
and tumor volume showed a negative correlation in WT mice exposed to nitro-oleate (P < 0.03). This correlative association was absent in KI treated with the nitro-
lipid, as well as either genotype administered vehicle alone. (G) EET/DHET ratios in plasma of WT or KI mice treated with or without nitro-oleate. The concentration
of plasma the EET/DHET for the 11 (12) or 8 (9) regioisomers showed a trend towards increasing in WT, but not KI, mice harbouring tumors exposed to nitro-oleate
(N=3 mice per experimental group) (H) More isolectin B4 and CD31 positive cells were detected in tumor sections isolated from WT mice exposed to nitro-oleate
compared to vehicle. In contrast, nitro-lipid treatment did not increase expression in tumors implanted in C521S sEH KI mice (N=4 mice per experimental group). (I)
Plasma IL-1β and IL-12p70 was significantly decreased in WT mice exposed to nitro-oleate, with a similar downward trend observed for IL-6 and IL-10. This plasma
cytokine-lowering by nitro-oleate was not observed in the KI mice, but it was notable they had basally low levels, comparable to those in the vehicle control group
(N=4 mice per experimental group). Cytokine expression in tumor tissue showed a similar trend to their expression in plasma. *P < 0.05 significantly different
compared to WT or vehicle control group. #P < 0.05 significantly different compared to vehicle treated KI group. The biochemical and histological analyses
reported in panels D-I were performed on samples collected on day 16 of the protocol.
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through increasing abundance of EETs. For example, mice treated with
the sEH inhibitor AUDA showed significantly reduced inflammation
when exposed to lipopolysaccharide [42]. In the studies reported here,
nitro-oleate reduced the expression of pro-inflammatory IL-1β, IL-6 and
IL-12. As these cytokines have been shown to mediate tumor growth
[43–45], it is possible, as considered above, that this anti-inflammatory
action of the nitro-lipid counters growth potentiation arising from sEH
inhibition and increased angiogenic EETs. This may explain why the
nitro-lipid did not significantly increase growth of tumors implanted
into WT mice. Woodcock et al. showed that nitro-oleate reduced triple-
negative breast tumor growth [22], which was attributed to its anti-
inflammatory, as they like us observed a reduction in cytokines. Whilst
we did not see a reduction in LLc1 tumor growth upon exposure to
nitro-oleate, there were differences in its dose, route and duration of
administration, which together with etiological differences between
disparate cancers, makes direct comparisons difficult. It is also notable
that samples from patient with triple-negative breast cancer had high
levels of EETs and lower amounts of sEH compared to those from triple-
positive controls [46]. Furthermore, EETs stimulated triple-negative
breast tumor growth via activating the phosphoinositide 3-kinase-pro-
tein kinase-B pathway [19].
5. Conclusion
In conclusion, C521-dependent inhibition of sEH by nitro-oleate
robustly promoted proliferation and migration of ECs or LLc1 cells in
vitro. However, when the LLc1 cancer cells were implanted into mice,
there was not clear evidence of growth promotion induced by the nitro-
lipid, which may be due to the anti-inflammatory actions it con-
comitantly exerted.
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